WASHINGTON, DC—April 9, 2015—Kineta, Inc., a biotechnology company focused on the development of immune modulating drugs for infectious diseases, today released new data showing its vaccine adjuvants boosting the protection of influenza vaccines in animal models. The Kineta adjuvant system controls influenza infection by enhancing the antiviral cellular immune response and boosting the production of functional antibodies. Adjuvants are molecules added to a vaccine to improve the body’s vaccine immune response. They were discovered through Kineta’s proprietary AViid™ discovery platform, which is focused on the small molecules that activate the IRF-dependent immune pathways. The data were presented by Kineta’s Dr. Chelsea Olsen, Associate Director of Program Management and Virology in an oral presentation at the World Vaccine Congress during the Influenza and Respiratory segment of the conference.

“Our vaccine adjuvants enhance the protection conferred by existing influenza vaccines as demonstrated in lethal mouse infection models, and are also dose sparing and have the potential to strengthen the effectiveness of a variety of vaccines,” Dr. Olsen stated. “In
addition, unlike conventional vaccine adjuvants, our host directed small molecule compounds stimulate innate antiviral pathways which results in a more specific response,” Olsen concluded.

Kineta’s small molecule adjuvant program is being developed for a highly pathogenic influenza vaccine virus to provide antigen sparing and heterologous protection against diverse flu strains. This novel class of immune modulating compounds have the potential to reduce the vaccine dose, increase the efficacy of a broad spectrum of vaccines and enhance cross protection. Additional Kineta compounds with unique immune-modulatory properties offer the potential to develop novel adjuvants for vaccines targeting dengue virus and respiratory viral infections.


#####

**Kineta, Inc.** is a Seattle-based privately held biotechnology company specializing in clinical advancement of novel drug candidates derived from leading edge scientific research. Our world class scientists are pioneers in developing life-changing classes of new drugs designed to be more effective and safer than current medicines. Kineta seeks to improve the lives of millions of people suffering from autoimmune and viral diseases and from severe pain. Our progressive business model focuses on targeting unmet medical needs and rapid achievement of important clinical milestones. For more information on Kineta, Inc. visit our website, [www.Kinetabio.com](http://www.Kinetabio.com)

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for disease specific development activities. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, pre-clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Contact Dan Eramian  deramian@kineta.us  206-518-5566